Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GelTex Pharmaceuticals (GELX) -- Ignore unavailable to you. Want to Upgrade?

To: NY0001 who wrote (35)	10/25/1997 12:09:00 PM
From: James Silverman	Read Replies (1) \| Respond to of 127

Neuro, First I should preface this by saying I am not knowledgeable about neutraceuticals or how Big Pharma feels they fit into their grand schemes. I have never looked at Forbes Medi-Tech, Raisio or Phytrol. KOSP is not a neutraceutical firm. They are essentially a drug delivery firm and have developed, to market, a once daily Niacin pill that has very beneficial impacts upon lipids, in particular HDL, tg's and lp(a). KOSP chose not to outlicense the drug to big pharma and as such is in the midst of building a roughly 200 person sales force. As far as vertical products in the same market, you would have to look at what the big prescription cholesterol players are doing: WLA, BMY, MRK. J&J has no real foothold in the statin market as far as I know. Again, despite what inroads neutraceuticals make in the food supplement market, I do not see them severely biting into the prescription cholesterol market to any serious degree, at the very least, not for a number of years. This has zero to do with whether they will be successful or not. Its apples and oranges as far as I am concerned, where one areas success does not necessarily mean anothers failure. I apologize to GELX followers for the departure from the topic at hand. Regards, Jim